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Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action
of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt
signaling. Blockade of sclerostin binding to low-density lipoprotein receptor-related proteins 5 and 6
(LRP5 and LRP6) allows Wnt ligands to activate canonical Wnt signaling in bone, increasing bone for-
mation and decreasing bone resorption, making sclerostin an attractive target for osteoporosis therapy.
Because romosozumab is a bone-forming agent and an activator of canonical Wnt signaling, questions
have arisen regarding a potential carcinogenic risk. Weight-of-evidence factors used in the assessment of
human carcinogenic risk of romosozumab included features of canonical Wnt signaling, expression
pattern of sclerostin, phenotype of loss-of-function mutations in humans and mice, mode and mecha-
nism of action of romosozumab, and ﬁndings from romosozumab chronic toxicity studies in rats and
monkeys. Although the weight-of-evidence factors supported that romosozumab would pose a low
carcinogenic risk to humans, the carcinogenic potential of romosozumab was assessed in a rat lifetime
study. There were no romosozumab-related effects on tumor incidence in rats. The ﬁndings of the
lifetime study and the weight-of-evidence factors collectively indicate that romosozumab administration
would not pose a carcinogenic risk to humans.
© 2016 Amgen Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Romosozumab is a humanized immunoglobulin (Ig) G2 mono-
clonal antibody (Ab) that binds and blocks the action of sclerostin, a
protein secreted by osteocytes that is an extracellular inhibitor of
canonicalWnt signaling and bone formation (Poole et al., 2005; van
Bezooijen et al., 2004). Using Kinetic Exclusion Assay technology,
romosozumab has been found to bind to human, cynomolgus
monkey, and rat sclerostin with measured dissociation constants
(Kd) of 11 pM, 23 pM, and 3 pM, respectively (Gong et al., 2016).
Blockade of sclerostin binding by romosozumab to low-density li-
poprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) allowsnc. This is an open access article uWnt ligands to activate canonical Wnt signaling in bone and in-
crease bone formation (Baron and Kneissel, 2013; Gong et al., 2016).
Activation of canonical Wnt signaling by romosozumab or a rat
surrogate Ab with the same complementarity-determining region
(sclerostin Ab [Scl-Ab]) has been demonstrated in vitro and in vivo
(Gong et al., 2016; Nioi et al., 2015; Taylor et al., 2016). Currently
under investigation in clinical trials, romosozumab administered at
210 mg once monthly for 12 months has been demonstrated to
increase bone formation markers and bone mass in humans
(McClung et al., 2014).
Consistent with the high bone mass phenotype of homozygous
and heterozygous mouse models and human loss-of-function (LOF)
Sclerostin (SOST) mutations, romosozumab or Scl-Ab increases bone
formation, mass, and strength in ovariectomized rats, aged male
rats, and gonad-intact female and male cynomolgus monkeys (Linder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
Ab antibody
aBMD areal bone mineral density
aBMC areal bone mineral content
ADA antidrug antibody
ANOVA analysis of variance
AUC area under the curve
BFR/BS bone formation rate, surface referent
BL baseline
BMC bone mineral content
BMD bone mineral density
CA serum calcium
DJD degenerative joint disease
DXA dual-energy X-ray absorptiometry
Ec endocortical
FDA Food and Drug Administration
GLU glucose
GSK3 glycogen synthase kinase 3
HBM high bone mass
hPTH human parathyroid hormone
HT hematocrit
ICH International Council for Harmonisation
Ig immunoglobulin
IHC immunohistochemistry
ISH in situ hybridization
L labeled
LOF loss-of-function
LRP low-density lipoprotein receptor-related protein
MPV mean platelet volume
MS/BS mineralizing surface/bone surface
NOAEL no-observed-adverse-effect-level
OSA osteosarcoma
PHOS phosphorus
PLT platelets
Pm perimeter
pQCT peripheral quantitative computed tomography
Ps periosteal
PTH parathyroid hormone
QM once monthly
QW once a week
RBC red blood cells
RETIC reticulocytes
RNA-Seq ribonucleic acid sequencing
RT-PCR reverse transcriptase polymerase chain reaction
SC subcutaneous
Scl-Ab Sclerostin antibody
SD Sprague-Dawley
SD standard deviation
SEM standard error of the mean
SOST Sclerostin
vBMC volumetric bone mineral content
wk week
yr year
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In animal models, sclerostin inhibition by a Scl-Ab results in a
decrease or no change in bone resorption (Li et al., 2010; Ominsky
et al., 2011; Stolina et al., 2014). In humans, increases in bone mass
are associated with transient increases in bone formation markers
and sustained decreases in resorption markers (McClung et al.,
2014; Padhi et al., 2011).
Because romosozumab is a bone-forming agent and an activator
of canonical Wnt signaling, questions have arisen regarding a po-
tential carcinogenic risk (Baron and Hesse, 2012; Hoeppner et al.,
2009; Lewiecki, 2014; Schett and Bozec, 2014). These concerns
stem from both the association of mutations in the canonical Wnt
pathways with human cancers arising through activating muta-
tions or epigenetic changes in the intracellular signaling compo-
nents (Anastas andMoon, 2013; Kansara et al., 2009; Polakis, 2007),
and experimental overexpression of Wnt ligands, which results in
hyperplasia followed by neoplasia (Bradbury et al., 1995; Lane and
Leder, 1997; Nusse and Varmus, 1982; Roelink et al., 1990). How-
ever, inactivating mutations in genes thought to inhibit Wnt
signaling (notably extracellular inhibitors) have generally not been
associated with cancer but rather with non-neoplastic disorders
(Anastas and Moon, 2013). Bone neoplastic ﬁndings have been
observed with other bone-forming agents, speciﬁcally human
parathyroid hormone (hPTH; hPTH [1e84] and other analogues). In
2-year rat studies with hPTH and other analogues and a hPTH-
related protein analogue, a high incidence of osteosarcomas
(OSAs) associated with preneoplastic bone changes (osteoblast
hyperplasia and stromal proliferation) and benign bone tumors was
observed in both F344 and Sprague-Dawley (SD) rats, with inci-
dence increasing with dose (Jolette et al., 2006, 2014; Vahle et al.,
2002; Watanabe et al., 2012). For this reason, the prescribing in-
formation for the only Food and Drug Administration (FDA)e
approved bone-forming agent teriparatide (hPTH [1e34]) has ablack box warning for potential risk of OSA.
Many factors contribute to the overall assessment of the human
carcinogenic risk of romosozumab based on a weight-of-evidence
approach described by an International Council for Harmo-
nisation (ICH) S1 Expert Working Group for small molecule
drugsdICH S1 regulatory notice 10 March 2015 (ICH, 2015). Key
factors contributing to the weight-of-evidence for carcinogenic
potential for romosozumab include features of canonical Wnt
signaling, the restricted expression pattern of sclerostin, human
and mouse genetic LOF data, the mode and molecular mechanism
of action of romosozumab compared with other bone-forming
agents, and ﬁndings in the chronic toxicology studies in rats and
cynomolgus monkeys. Key data for each of these factors are pro-
vided below, with more detailed information provided in the
Supplemental Materials section 2:
 As a morphogen pathway during development, canonical Wnt
signaling evolved to be a highly spatially and temporally regu-
lated autocrine/paracrine signaling pathway (Supplemental
Materials section 2.1).
 As an autocrine/paracrine pathway, activation of canonical Wnt
signaling will be restricted to tissues that express sclerostin. The
tissue expression pattern of sclerostin is limited largely to cells
encased in a mineralized matrix, with the major site of
expression in osteocytes (Table S1).
 The bone-speciﬁc phenotype of LOF SOST mutations in humans
and mice further supports the largely restricted effects of loss or
deﬁciency of sclerostin to bone, with no reported increases in
cancer in either humans or mice with LOF mutations
(Supplemental Materials section 2.2).
 Romosozumab has a unique mode of action at the bone tissue
level compared with the only approved bone-forming agent
teriparatide (hPTH [1e34]). In contrast to teriparatide, which
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bone formation is transiently increased with romosozumab,
displaying pronounced self-regulation of bone formation,
accompanied by sustained inhibition of bone resorption in
humans (McClung et al., 2014). In rats, maintenance of bone
formation by hPTH (1e34) requires a higher osteoblast density
and greater number of osteoprogenitors than with romosozu-
mab, indicating a potentially greater stimulation of progenitor
pool proliferation with hPTH (1e34) (Supplemental Materials
section 2.3).
 In rats, activation of canonical Wnt signaling in bone by a Scl-Ab
results in acute upregulation of a small number of canonical
Wnt target genes with known roles in osteoblastogenesis
accompanied by upregulation of numerous bone matrix genes.
This transcriptional signature is similar in all subpopulations of
mature osteoblast lineage. The self-regulation of bone formation
that occurs with long-term Scl-Ab treatment is temporally
associated with a coordinated reduction in osteoprogenitor
numbers and transcriptional regulation of pathways in the
osteocyte that would limit mitogenesis and cell cycle progres-
sion, with upregulation of tumor suppressor pathways including
p53, retinoblastoma, and cyclin-dependent-kinase inhibitor 1A
and 2A (Supplemental Materials section 2.4.
 In 6-month toxicity studies with a 14-week recovery period, rats
and cynomolgus monkeys were administered romosozumab at
weekly (QW) subcutaneous (SC) doses up to 100 mg/kg,
resulting in exposure 38- to 93-fold greater than the clinical
exposure. Romosozumab-related effects were either a direct or
an indirect consequence of the pharmacologic effects on bone.
There was no evidence of histopathologic risk factors for rat
neoplasia (test articleerelated hypertrophy, hyperplasia, or
altered foci) (Reddy et al., 2010; Sistare et al., 2011) in any organ
at the end of the treatment or recovery period (Supplemental
Materials section 2.5).
Although these weight-of-evidence factors support that romo-
sozumab would pose a low risk for carcinogenicity, the carcino-
genic potential of romosozumab was evaluated in a lifetime
pharmacology (carcinogenicity) study in rats at the request of the
regulatory agencies as the ﬁnal element of the risk assessment and
is the main focus of this paper. Studies that contributed to or were
conducted in support of the overall carcinogenic risk assessment of
romosozumab are presented in the Supplemental Materials).
Because romosozumab is immunogenic in rats and the long-term
consequences of lifetime exposure to an immunogenic foreign
were unknown at the time of the conduct of the lifetime study, a
null Ab lifetime study in rats was conducted in parallel with an IgG2
monoclonal Ab that is pharmacologically inactive but with similar
immunogenicity in rats as romosozumab, which is summarized in
Supplemental Materials section 3.
2. Materials and methods
2.1. Animal care
The rat lifetime studies were conducted at Charles River Labo-
ratories, Montreal, Canada, in accordance with the most recent
version of the United States Food and Drug Administration Good
Laboratory Practice Regulations (2 1 CFR Part 58); the Japanese
Ministry of Health, Labor, and welfare Good Laboratory Practice
Standards, Ordinance 2 1; and the Organisation for Economic Co-
operation and Development Principles of Good Laboratory Prac-
tice, C (97) 186/Final and any applicable amendments. The studies
were also conducted in accordance with the testing facility Stan-
dard Operating Procedures, protocol, and protocol amendments.Rats were cared for in accordance with the Guide for the Care and
Use of Laboratory Animals. All research protocols were approved by
the Institutional Animal Care and Use Committee. Full details of
animal care can be found in the Supplemental Materials section 1.
2.2. Romosozumab rat lifetime pharmacology study
Male and female SD (CD® IGS, Charles River Canada, St. Constant,
Canada) rats were divided into four treatment groups each and
received vehicle (n ¼ 60/sex) or 3 mg/kg (n ¼ 150/sex), 10 mg/kg
(n ¼ 80/sex), or 50 mg/kg (n ¼ 80/sex) romosozumab QW by SC
injection beginning at 8 weeks of age. Group sizes were powered to
allow for removal of neutralizing antidrug Ab (ADA)epositive rats
from study. Animals were removed from the treatment groups
based on ADA status and drug concentration at week 12 to reduce
the group size to a target 60 animals/sex/group. The 3, 10, and
50mg/kg doses were predicted to provide exposure margins of 0.6-
, 3.9-, and 19-fold to clinical exposure based on area under the
curve, respectively. Because of the concern for potential adverse or
fatal neurological consequences that could result in early deaths or
teminations as a result of excessive bone growth with lifetime
exposure to romosozumab, a dose higher than 50 mg/kg was not
included. The following parameters and end points were evaluated:
clinical signs, body weights, food consumption, serum drug con-
centration and neutralizing ADA status, macroscopic pathology,
and histopathology. An expanded list of selected bones was
collected for microscopic evaluation that included the calvarium,
right tibia, left femorotibial joint (distal femur and proximal tibia),
lumbar vertebrae 5e6, sternum, and nasal cavity Level II (maxillary
incisors). Whole body radiography was performed on scheduled
and unscheduled necropsies to detect abnormalities in the skeleton
and alterations in soft tissue radiodensity (eg, mineralization) to
direct trimming of additional tissues for histopathology. To docu-
ment sustained pharmacodynamic effects in terminal necropsy
animals, ex vivo peripheral quantitative computed tomography
(pQCT) analyses (XCT Research SAþ bone scanner, software version
6.20 C, Stratec Biomedical, Birkenfeld, Germany) at the femur
metaphysis and diaphysis were performed on terminally eutha-
nized animals.
2.3. Statistical analyses
The survival function of each group was estimated using the
Kaplan-Meier product-limit method applied on daily intervals, and
graphs were produced. For the incidence tumor data, neoplastic
lesions categorized as palpable were analyzed in a mortality-
independent context according to Peto's onset rate method (Peto
et al., 1980). Tumors categorized as nonpalpable were analyzed
using the mortality-dependent method. In this context, each
neoplastic ﬁnding was classiﬁed as the cause of death (fatal) or not
the cause of death (incidental) and was analyzed accordingly using
Peto's death rate and the prevalence methods, as per the US FDA's
Guidance for Industry (US FDA, 2001).
The incidence neoplastic data were also statistically analyzed
using the poly-3 methodology, as ﬁrst described by Bailer and
Portier (Bailer and Portier, 1988) and modiﬁed by Bieler and Wil-
liams (Bieler and Williams, 1993). For each animal, the tumor-
bearing animals and the nonetumor-bearing animals that lived
the full dosing period were assigned a weighted at-risk score of 1.
Nonetumor-bearing animals that died before the end of the full
dosing period were assigned a weighted at-risk score based on the
time of death. The weighted number of animals at risk in each
group represented the sum of the corresponding weighted at-risk
scores; this sum was used in a modiﬁed one-sided Cochran-
Armitage test to assess the signiﬁcance of tumor rate increase via
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Signiﬁcance was assessed according to the tumor prevalence
classiﬁcation (common or rare) and recommendations by the FDA.
Common tumors were deﬁned as having a historical frequency
greater than 1% and tested at the 0.01 signiﬁcance level for the
overall trend test and 0.025 signiﬁcance level for pairwise com-
parisons. Rare tumors were deﬁned as having a historical frequency
less than or equal to 1% and tested at the 0.05 signiﬁcance level for
the overall trend test and 0.10 signiﬁcance level for pairwise
comparisons.3. Results
Following the removal of ADA-positive animals at week 12, a
target of 60 animals/sex/group was achieved in all groups except
for themales at 50mg/kg (n¼ 54), due to a high rate of neutralizing
ADAs in this group. At week 12, the mean ± standard deviation
serum romosozumab concentration in ﬁnal allocation animals at 3,
10, and 50mg/kg was 4.91 ± 1.79, 74.6 ± 23.8, and 836 ± 215 mg/mL,
respectively, in females and 9.66 ± 2.86, 79.5 ± 18.7, and
589 ± 234 mg/mL, respectively, in males.
Males were terminated at Week 91 and females at Week 98,
because the number of rats in the vehicle groups had reached 20.
Romosozumab had no effects on clinical observations, body weight,
or food consumption. Between 36 and 43 rats per sex per treatment
group died or were euthanized before the end of the treatment
period. There was no test articleerelated effect on survival using
Log rank test (p¼ 0.9751 for males and p¼ 0.5922 for females). The
survival-curve estimates based on the Kaplan-Meier product limitFig. 1. The survival curve estimates based on the Kaplan-Meiemethod are shown in Fig. 1. Pituitary gland adenoma (pars distalis)
was the most common cause of death in both sexes. Romosozumab
had no effect on the incidence of fatal pituitary adenoma or the
incidence of all other fatal neoplastic and non-neoplastic ﬁndings;
the causes of death observed were comparable to the vehicle
control group and of a similar nature as observed in this strain of
rat.
pQCT analyses conﬁrmed maintenance of pharmacological ef-
fects at study termination. Compared with vehicle controls, total
volumetric bone mineral content (vBMC) of the distal femur met-
aphysis increased approximately 2x and 2.6x in males and females,
respectively (Fig. 2A and B), and trabecular vBMC increased
approximately 3.7x and 5.5x, respectively (data not shown). The
increase in bone mass is evident in representative pQCT images of
the femoral metaphysis (Fig. 2C and D) and correlative histologic
ﬁndings (Fig. 2E and F). Diaphyseal data and pQCT images are
presented in Fig. S6.
Whole body radiography revealed a generalized increase in
bone radiopacity in most rats treated with romosozumab at all
doses (Table 1; Fig. 3), consistent with the expected pharmacody-
namic response and reﬂecting hyperostosis, ie, increased bone
observed histologically. Radiographic bone production, bone loss,
or mixed reaction was noted in both vehicle- and romosozumab-
treated rats at miscellaneous bone sites or in the femur and tibia
(Table 1); these generally correlated with macroscopic and micro-
scopic changes. No radiographic ﬁndings other than increased
radiodensity were considered test articleerelated except for bone
loss (a reduction in bone accrual) at the distal radius (bone
miscellaneous; Table 1). This ﬁnding correlated microscopicallyr product limit method for male (A) and female (B) rats.
Fig. 2. vBMC of the distal femoral metaphysis in male (A) and female (B) rats at scheduled terminal necropsy. pQCT images of femur metaphysis frommales (C) and females (D) at 0,
3, 10, and 50 mg/kg (left to right). Metaphyseal slice was obtained at a position 15% (males) and 18% (females) of the total femur length proximal to the distal end of the femur.
Images selected are from animals whose vBMC values were close to the group means. Correlative histology ﬁndings in the femur of males (E) and females (F) at 0, 3, 10, and 50 mg/
kg (left to right). pQCT ¼ peripheral quantitative computed tomography; SD ¼ standard deviation; vBMC ¼ volumetric bone mineral content.
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compared with other examined skeletal sites and was nonlytic in
nature. The secondmost frequent radiographic ﬁnding in all groups
was bone production correlating with osteophytes and periosteal
new bone at the tibial-tarsal joint associated with chronic podo-
dermatitis, a common ﬁnding in aging rats (Table S7). Romosozu-
mab treatment did not alter the incidence or severity of this
ﬁnding.
There was no neoplastic change attributed to the QW SC
administration of romosozumab in rats for up to 91/98 weeks. The
benign and malignant tumors in both control- and romosozumab-
treated groups were considered spontaneous in origin, as is
commonly observed in this strain and age of rat, and occurred at a
similar incidence compared with vehicle controls, and/or were
within the historical data range for the Test Facility.
A slight increased incidence of adrenal cortical adenoma, acommon tumor, was noted in males at 10 mg/kg and was statisti-
cally signiﬁcant by pairwise comparison only (p ¼ 0.0169 Peto's,
p ¼ 0.0149 poly-3; Table 2). However, this ﬁnding was not
considered related to romosozumab because the incidence was
within the historical data range for the test facility (0%e10%) and
there was neither a dose-related trend nor any precursor preneo-
plastic change. Renal lipoma, a rare tumor, was signiﬁcant only in
females based on the trend test (p¼ 0.0486 Peto's, p¼ 0.0441 poly-
3). The incidence of renal lipoma noted in females at 50 mg/kg was
above the testing facility historical data range (5% vs 0%e4%).
However, this ﬁnding was not considered related to romosozumab
because of the low incidence, lack of preneoplastic precursor le-
sions, and comparable nature and morphology to the renal lipoma
in the control females.
Numerical imbalances were noted in the incidence of a few
common tumors; p values did not meet criteria for statistical
Table 1
Incidence of radiographic ﬁndings.
Male Female
Group: 1 2 3 4 1 2 3 4
Dose (mg/kg/dose): 0 3 10 50 0 3 10 50
Animals examined: 60 60 60 54 60 60 60 60
Radiographic ﬁndings Incidence
Increased bone radiopacity 0 44 53 46 2 58 56 55
Bone miscellaneous
Bone loss 1 1 3 4 1 3 2 7
Bone production 7 1 2 6 16 21 21 20
Mixed reaction 6 2 6 2 3 3 0 0
Bone femur
Bone loss 1 0 2 0 0 0 0 0
Bone production 1 2 1 0 0 0 0 0
Mixed reaction 1 0 0 0 0 1 0 0
Bone tibia
Bone loss 0 1 0 1 0 0 0 0
Bone production 4 4 8 2 1 2 3 2
Mixed reaction 0 0 1 0 0 0 0 0
Fig. 3. Whole-body radiographs from a vehicle- (A) and romosozumab-treated
(50 mg/kg) (B) female rat illustrating the romosozumab-related generalized increase
in skeletal radiodensity.
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of these tumors (Table 2). These included islet cell adenoma (fe-
males at 50 mg/kg) and combined islet cell adenoma and carci-
noma (males at 10 mg/kg). In addition to lack of statistical
signiﬁcance, the absence of an association to romosozumab is
further supported by the low incidence of these tumors, which was
lower or within the range of the testing facility historical data (islet
cell adenoma:male 0%e13.33%, female 0%e8.33%; carcinoma: male
1%e11.67%, female 0%e6.67%; combined adenoma/carcinoma:
male 1.79%e19%, female 0%e13.33%), and the lack of precursorpreneoplastic islet cell changes in this study. In the concurrent
lifetime study conducted with an IgG2 Ab that is pharmacologically
inactive with similar immunogenicity as romosozumab in rats, the
incidence of islet cell tumors in saline, vehicle, and IgG2 treatment
groups aligned with historical control incidence (for details, see
Supplemental Materials section 3), conﬁrming that the observed
imbalance was related to the low incidence in the vehicle-treated
group in this study.
Other common tumors with numerical imbalances that did not
reach statistical signiﬁcance were benign pheochromocytoma and
thyroid C-cell adenoma in females at 3 mg/kg and keratoacan-
thoma in the skin of males at 10 mg/kg (Table 2). In addition to lack
of statistical signiﬁcance, there was also no relationship to romo-
sozumab, supported by the absence of a dose-response relation-
ship, the absence of precursor preneoplastic change, and the
incidence of tumors falling within the historical data range
(pheochromocytoma 0%e10%, thyroid C-cell adenoma 2.67%e
20.54%, and keratoacanthoma 0%e13.39%).
Two OSAswere noted in themales at 50mg/kg. The incidence of
OSA in males was not statistically signiﬁcant using both Peto's
survival-adjusted one-tailed overall trend test (p ¼ 0.08333) and
pairwise comparison (p¼ 0.2979) or using poly-3 method for trend
(p ¼ 0.0604) and pairwise comparison (p ¼ 0.24). One OSA was
noted in the left proximal tibia at Day 572. This change was not
detected macroscopically and correlated with the focal bone loss
noted radiographically. There were no metastases noted, and the
cause of death of this animal was attributed to a pituitary adenoma.
The second OSA was noted on the frontal bone/skull at Day 587. In
this case, the OSA was considered the cause of death due to
compression of the brain and correlated with the gross and
radiographic observations. There were no metastases noted.
Bone neoplasms and OSAs are rare in SD rats. The incidence of
spontaneous OSA in male and female SD rats in 2-year studies at
the test facility ranged from 0% to 3.33%. The incidence of OSA in
males at 50 mg/kg was 3.7%, marginally higher than the historical
range due to the exclusion of ADA-positive animals, resulting in 54
vs 60 animals in the high-dosemales. However, the incidence in the
entire population of rats in this study was 0.42%, consistent with
the historical average incidence of 0.38% across studies conducted
at the Testing Facility. The historical data in SD rats are based on
studies where whole body radiography was not conducted and
detection of OSA was limited to microscopic evaluation of sternum
and/or single long bone and macroscopic abnormalities. Historical
data from studies where whole body radiographs were conducted
to detect bone neoplasms and other bone changes in SD rats are not
currently available. It is reasonable to assume that whole body ra-
diographs and expanded bone evaluation would signiﬁcantly in-
crease the sensitivity for detection of bone lesions. Such an
increased sensitivity is illustrated by the incidence of odontoma in
all female groups in the current study versus historical controls
(Table S7) and detection of an occult osteochondromada rare tu-
mor not in the test facility's historical datadin the null Ab study
(Table S6). There were no other bone tumors in this study, in
contrast to results of long-term administration of parathyroid
hormone (PTH) (1e34) and PTH (1e84) in F344 and PTH (1e34) in
SD rats that resulted in OSA, osteoblastoma, and osteoma (Jolette
et al., 2006; Vahle et al., 2002; Watanabe et al., 2012). Therefore,
the OSAs observed in males at 50 mg/kg were considered sponta-
neous in origin based on the low incidence within the range of
historical data at the test facility, late onset, solitary nature, and lack
of a continuum that includes precursor proliferative osteoblastic
changes including osteoblast hyperplasia, focal stromal prolifera-
tion, and benign bone tumors (Vahle et al., 2004). Focal osteoblast
hyperplasia was noted in the tibial epiphysis of a single male at
10 mg/kg found dead at study day 534. However, focal osteoblast
Table 2
Incidence of selected tumors in male and female Sprague-Dawley rats treated with romosozumab.
Males Females
Romosozumab dose (mg/kg/wk): 0 3 10 50 0 3 10 50
Animals examined: 60 60 60 54 60 60 60 60
Tissue Incidence
Adrenal gland Adenoma, adrenal corticala,* 0 2 6* 2 6 3 1 7
Kidney Lipoma, renala,** 0 0 0 1 1 0 0 3**
Thyroid gland Adenoma, C-cellb 8 10 4 6 5 11 8 8
Pancreas Adenoma, islet cellb 1 1 3 4 0 0 3 3
Pancreas Carcinoma, islet cellb 0 0 3 2 1 0 1 0
Pancreas Combined adenoma/carcinoma, islet cellb 1 1 6 6 1 0 4 3
Skin Keratoacanthomab 2 1 7 0 0 1 0 1
Adrenal gland Pheochromocytoma, benignb 4 3 6 3 2 8 2 0
* p ¼ 0.0486, trend test. ** p ¼ 0.0169, pairwise comparison.
a : Incidence of tumors that was signiﬁcant by either trend test or pairwise comparison.
b Incidence of tumors that displayed numerical imbalances.
L. Chouinard et al. / Regulatory Toxicology and Pharmacology 81 (2016) 212e222218hyperplasia, which can occur as a spontaneous ﬁnding, was also
observed in the vertebrae of a saline control SD male in the con-
current null Ab study (Table S6). Focal osteoblast hyperplasia has
been reported at a low incidence in control Fischer rats (JoletteFig. 4. Incidence of focal osteoblast hyperplasia and benign and malignant bone tumors
romosozumab QW in the lifetime pharmacology study. PTH ¼ parathyroid hormone; SD ¼et al., 2006). The incidence of preneoplastic bone ﬁndings and
benign and malignant bone tumors from PTH studies reported by
Vahle and colleagues, Jolette and colleagues, and the current study
is compared in Fig. 4.in F344 rats administered daily PTH (1e34) or PTH (1e84) and SD rats administered
Sprague-Dawley.
Table 3
Romosozumab-related microscopic ﬁndings.
Males Females
Dose (mg/kg/wk): 0 3 10 50 0 3 10 50
Animals examined: 60 60 60 54 60 60 60 60
Microscopic ﬁndings Incidence
Hyperostosis (femur)a
Number affected 0 43 60 52 0 45 60 60
Minimal 0 26 3 4 0 31 3 0
Slight 0 11 20 3 0 12 21 0
Moderate 0 4 36 29 0 2 25 6
Marked 0 2 1 16 0 0 10 49
Severe 0 0 0 0 0 0 1 5
Extramedullary hematopoiesis (liver)
Number affected 5 13 13 12 22 25 41 39
Minimal 5 12 11 10 17 23 36 34
Slight 0 1 2 2 5 2 5 5
Extramedullary hematopoiesis (spleen)
Number affected 13 38 44 40 37 49 57 60
Minimal 6 24 33 24 13 13 8 12
Slight 3 8 8 9 10 13 19 21
Moderate 3 4 3 5 9 21 23 16
Marked 1 2 0 2 5 2 7 9
Severe 0 0 0 0 0 0 0 2
a Other bones examined are not presented in this table.
Fig. 5. Cancellous bone surfaces and adjacent marrow in control- (A) and romosozu-
mab 50 mg/kg-treated (B) female rats, illustrating thick trabeculae lined by normal
reactive osteoblasts and normal hematopoietic marrow with no evidence of woven
bone or stromal cell proliferation in response to romosozumab treatment. Scale bar
represents 200 mm.
Fig. 6. Incidence of proliferative changes and benign and malignant bone tumors in
male F344 and Sprague Dawley rats administered hPTH (1e34). Incidence in Sprague
Dawley rats is reported at the highest dose tested in the study (Watanabe et al., 2012)
with incidence from F344 (Vahle et al., 2002).
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administration of romosozumab in this lifetime pharmacology
study were limited to a dose-dependent hyperostosis involving the
epiphysis and metaphysis as well as the cortex of all bones exam-
ined, resulting in reduction of the marrow space (Table 3). The
thicker trabeculaewere composed ofmature lamellar bone lined by
normal nonreactive osteoblasts morphologically indistinguishable
from vehicle-treated rats. There was no woven bone or other
morphological changes indicating altered bone quality (Fig. 5). The
hyperostosis was of comparable severity among bone sites in agiven dose group. The incidence and severity of hyperostosis
correlated with the thickening of the bones observed macroscopi-
cally, the increased bone radiopacity of the skeleton noted radio-
graphically, and the densitometry (pQCT) data for terminal animals.
Other non-neoplastic changes attributed to romosozumab
included increased incidence/severity of splenic extramedullary
hematopoiesis in both sexes at  3 mg/kg, correlating with the
macroscopic observation of spleen enlargement. Increased inci-
dence of extramedullary hematopoiesis was also observed in the
liver of males at  3 mg/kg and females at  10 mg/kg. The splenic
and hepatic extramedullary hematopoiesis was considered
compensatory and secondary to the reduced bone marrow space as
a consequence of the generalized bone hyperostosis (Table 3). There
was an increased incidence of mononuclear cell inﬁltration noted at
injection sites of males at  3 mg/kg and females at  10 mg/kg, a
typical reaction associated with administration of foreign protein.
Findings from this lifetime study provided data addressing
several non-neoplastic theoretical concerns regarding clinical use
of romosozumab. These concerns are based on the tissue expres-
sion pattern of sclerostin, including in chondrocytes, cementocytes,
and mineralized/ossiﬁed vascular foci, where sclerostin inhibition
could theoretically exacerbate articular cartilage degeneration and
osteophyte formation, induce hypercementosis and/or dental tu-
mors, or exacerbate spontaneous mineralization/ossiﬁcation,
respectively. Notably, the incidence and/or severity of degenerative
joint disease (DJD), osteophytes, ectopic ossiﬁcation, mineraliza-
tion, and dental ﬁndings/tumors were not modiﬁed by romosozu-
mab treatment (Table S7).4. Discussion
In a lifetime pharmacology study in male and female SD rats,
there were no romosozumab-related effects on survival or tumor
incidence at QW doses up to 50 mg/kg. The lack of a test arti-
cleerelated effect on tumor incidence aligns with the weight-of-
evidence factors and ﬁndings in the chronic toxicity studies, in
which there was no evidence of hypertrophy, hyperplasia, or
atypical foci in any organ in rats or monkeys.
The concept that the local expression of sclerostin will limit the
responding tissues to those that express sclerostin is borne out in
the chronic toxicity (Supplemental Materials section 2.5) and life-
time studies. All ﬁndings were a direct or indirect consequence of
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primary target tissue where biological effects of sclerostin inhibi-
tion by romosozumab are evident. These data are also consistent
with the bone-speciﬁc phenotype of LOF mutations in humans and
mice. The lack of ﬁndings in other tissues that express sclerostin in
rats may be a consequence of the limited access of Scl-Ab to the
target cell (eg, chondrocytes or cementocytes) or redundant regu-
latory mechanisms. The bone-speciﬁc ﬁndings are in contrast to the
pathology observed with a glycogen synthase kinase 3 (GSK3) in-
hibitor that broadly activates canonical Wnt signaling by prevent-
ing b-catenin degradation. Inhibition of GSK results in hyperplastic
changes in numerous soft tissues in rats and dogs (Hall et al., 2015),
consistent with hyperplastic changes that occur with over-
expression of Wnt ligands in selected tissues (Bradbury et al., 1995;
Lane and Leder, 1997; Nusse and Varmus,1982; Roelink et al., 1990).
Although romosozumab is a bone-building agent, lifetime
administration did not result in the dose-dependent preneoplastic
bone changes and benign and malignant bone tumors that have
been observed with other bone-building agents in rats, speciﬁcally
PTH and related analogues. Although the PTH carcinogenicity
studies were conducted in F344 rats, a study in SD rats showed
similar responses to chronic PTH treatment with respect to bone
carcinogenicity (Fig. 6) (Watanabe et al., 2012). Therefore, the dif-
ferences in response to PTH and romosozumab are not strain-
related. The effects on bone mass at study termination were
similar at the highest doses in the hPTH (1e34) (75 mg/kg/d) (Vahle
et al., 2002) and romosozumab (50 mg/kg QW) studies compared
with concurrent controls, suggesting that the cumulative phar-
macodynamic effects of romosozumab and hPTH (1e34) on bone
were similar. Thus, a differential pharmacodynamic effect would
not explain the differences in tumor incidence between the two
studies.
The lack of bone carcinogenic responses with romosozumab
administration may be attributed to the transient nature of the
stimulation of bone formation with the coordinated reduction in
osteoprogenitor subpopulations, which would limit the prolifera-
tion drive on the progenitor pools (Ominsky et al., 2015; Taylor
et al., 2016). Reduction in progenitor number occurred coincident
with transcriptional changes that are consistent with an inhibition
of mitogenesis and cell cycle progression, which included activa-
tion of signaling through major tumor suppressor pathways, such
as p53 and Rb, in response to long-term romosozumab adminis-
tration in rats. p53 and Rb are recognized as potent regulators of
osteoblastogenesis and inhibitors of osteosarcomagenesis (Jones,
2011; Lengner et al., 2006; Liu and Li, 2010; Taylor et al., 2016;
Wang et al., 2006). In contrast, existing transcriptional data with
hPTH do not indicate sustained effects on genes involved in limiting
cell cycle progression and proliferation (Li et al., 2007; Qin et al.,
2005). Signiﬁcant regulation of cell cycle genes was not reported
in microarray analyses of calvaria from mice chronically treated
with hPTH (Gesty-Palmer et al., 2013), which may contribute to the
more sustained increases in bone formation observed with hPTH
and the increased numbers of osteoblasts and osteoprogenitors
relative to romosozumab (Ominsky et al., 2015).
It is notable that OSAs to date have not been associated with the
clinical use of teriparatide (hPTH[1e34]) (Andrews et al., 2012). The
apparent lack of translation of the rodent ﬁndings to humans may
relate to the restricted duration of treatment (18 months), limita-
tions of the currently available patient follow-up time in the For-
teo® Patient Registry (Harris et al., 2015), and fundamental
differences in responses of the rodent skeleton to long-term
hPTH(1e34). The increases in bone formation and resorption
appear to be sustained for a longer duration in rats compared with
humans, based on dosing duration relative to lifespan. In a
comparative clinical trial, increases in bone formation markersreturned to control levels within 6 months of romosozumab
treatment but were sustained over a 12-month period with ter-
iparatide treatment (McClung et al., 2014). However, normalization
of bone formation and resorption appears to occur eventually in
humans after 19 months of treatment with teriparatide, as histo-
morphometric indices of bone formation and resorption are similar
to pre-treatment values at that time (Jiang et al., 2003). In contrast,
dose-dependent increases in bone formation and resorption are
still evident at 12 months in rats given hPTH(1e84), a time repre-
senting approximately one-half the rodent lifespan (Fox et al.,
2006). Indeed, the carcinogenic effects of hPTH(1e34) on bone in
rats have been reported to be dose- and dosing-dura-
tionedependent (Vahle et al., 2004), suggesting that limiting the
duration of the increase in bone formationmay reduce carcinogenic
risk.
5. Conclusion
Administration of romosozumab to male and female SD rats for
up to 98 weeks did not increase the incidence of tumors, consistent
with the lack of neoplastic risk factors observed in the chronic
toxicology studies in rats and monkeys. Although romosozumab is
a bone-building agent, its mode and mechanism of action are
unique and distinct from hPTH, temporally limiting osteoblasto-
genesis and bone formation by coupling Wnt signaling with p53
and other tumor suppressor pathways that negatively regulate
osteoblastogenesis. The weight-of-evidence and ﬁndings in chronic
toxicity studies and the lifetime study in rats described here indi-
cate that romosozumab would not pose a carcinogenic risk to
humans.
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